Daiichi Sankyo, Syneos Health Form Strategic ADC Alliance

Daiichi Sankyo, Inc. has entered into a strategic agreement with Syneos Health to form a coalition to bring promising cancer therapies to patients, safely, and efficiently.
 
Syneos Health will provide strategic and operational services for three lead Daiichi antibody drug conjugates (ADC):  DS-1062, U3-1402 and DS-8201 (known as ENHERTU). The coalition expands a pre-existing relationship between the companies, further leveraging Syneos Health’s Syneos One product development model to de-risk and accelerate development.
 
The coalition will enable early strategic engagement of Syneos Health teams to inform critical drug development decision making from the start. Cross-functional teams from both companies will share therapeutic expertise and product development insights for optimal study designs and a consistent quality clinical delivery process.
 
The combined efforts of Daiichi and Syneos aims to provide a greater understanding of how patients are cared for, which workflows exist, and how clinical investigation can best be embedded in the clinic setting. Shared insights will also aim to enable optimized site selection and engagement to best address patient needs.